Safety Study of Nicotinamide to Treat Alzheimer's Disease

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to determine whether nicotinamide, or vitamin B3, is safe and effective in the treatment of Alzheimer's disease.

Key facts

Study ID

NCT00580931

Run by

University of California, Irvine

People needed

50

Starts

2008-01-01

Expected to finish

2014-07-01

Last updated by the study team

2017-01-25

Who can join

Age: 50 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of probable AD according to DSM-IV criteria
• Mild to moderate dementia based on Mini-Mental State Examination [MMSE] score between 13-25
• Minimum age 50 years
• Brain imaging (computed tomographic scan or magnetic resonance image) within 12 months consistent with a diagnosis of probable AD
• Hachinski Ischemic Score of <4.
• Stable doses of concomitant medications, including cholinesterase inhibitors (ChEIs) and/or memantine.

You may not qualify if…

• Dementia due to another cause
• Other neurological or psychiatric diseases
• Pseudodementia
• Unstable medical condition
• Initial treatment within 30 days of screening with a ChEI, memantine or any investigational drug
• History of alcoholism, drug abuse, liver disease, peptic ulcer disease
• Pregnancy, or the potential to become pregnant.

Where it is running

• UC Irvine School of Medicine — Irvine, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.